Quest Diagnostics Incorporated
As of Oct 23, 2026 close
- Market cap
- $27.09B
- P/E (TTM)
- 25.51
- Forward P/E
- 23.00
- Dividend yield
- 1.39%
- 52-week range
- $171.18$248.84
- Volume (live)
- -
- Avg. volume (3M)
- 1.15M
Quest Diagnostics Incorporated (DGX) Stock Price & Financial Analysis
Quest Diagnostics Incorporated Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $239.63 - $244.33 |
|---|---|
| 52-Week High | $248.84 |
| 52-Week Low | $171.18 |
| Open | $239.63 |
| Volume (last close) | 933.38K |
| Average Volume (3M) | 1.15M |
| Revenue (TTM) | 11.56B |
|---|---|
| Net Income (TTM) | 1.06B |
| Free Cash Flow (TTM) | 1.35B |
| EPS (TTM) | $9.46 |
| Profit Margin | 9.19% |
| Operating Margin | 14.19% |
| Return on Equity (ROE) | 14.13% |
| Debt to Equity | 0.75 |
| Annual Dividend | $3.38 |
|---|---|
| Dividend Yield | 1.39% |
| Payout Ratio | 35.73% |
| Last Dividend Ex-Date | Oct 6, 2026 |
| Market Cap | 27.09B |
|---|---|
| Shares Outstanding | 112.00M |
| P/E Ratio (TTM) | 25.51 |
| Forward P/E | 23.00 |
| Price to Sales (P/S) | 2.34 |
| Price to Book (P/B) | 3.60 |
| EV/EBITDA | 14.29 |
| 50-Day MA | $237.35 |
|---|---|
| 200-Day MA | $209.48 |
| 1-Year Change | +32.77% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Quest Diagnostics Incorporated at a Glance
As of the Oct 23, 2026 close, Quest Diagnostics Incorporated (DGX) has a market capitalization of $27.09B. The stock trades at 25.5× trailing earnings, 23.0× forward earnings and 2.3× sales. Over the trailing twelve months it earned $1.06B on revenue of $11.56B (a 9.2% profit margin) and generated $1.35B of free cash flow. Revenue grew 9.9% year over year.
As of its latest reported balance sheet, it holds $626.00M in cash and securities against $5.64B of debt, a net debt position of $5.02B.
Quest Diagnostics Incorporated pays a quarterly dividend totaling $3.38 per share a year, a 1.39% yield at the Oct 23, 2026 close, with a 36% payout ratio and 14 consecutive years of dividend increases.
The share price is up 32.8% over the past year. At $241.89 (the Oct 23, 2026 close) it sits near the top of its 52-week range of $171.18 to $248.84, above its 200-day moving average of $209.48.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $256.43, 6.0% above the Oct 23, 2026 close.
Frequently Asked Questions About Quest Diagnostics Incorporated
What is the current stock price for DGX?
As of the Oct 23, 2026 close, DGX stock trades at $241.89. The 52-week range is $171.18–$248.84, with a day range of $239.63–$244.33.
What is the P/E ratio for DGX?
As of the Oct 23, 2026 close, Quest Diagnostics Incorporated's trailing twelve-month (TTM) P/E ratio is 25.5, meaning investors pay $25.5 for every $1 of annual earnings. The forward P/E is 23.0, reflecting analyst expectations for future earnings. Quest Diagnostics Incorporated operates in the Healthcare sector.
Does DGX pay dividends?
Yes, Quest Diagnostics Incorporated pays a 1.39% annual dividend yield as of the Oct 23, 2026 close ($3.38 per share a year). The trailing twelve-month payout ratio is 35.7%. The most recent ex-dividend date was October 6, 2026.
What do analysts recommend for DGX?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for DGX is Buy. The average 12-month price target is $256.43, a 6.0% upside from the Oct 23, 2026 close of $241.89.
What is the market cap of DGX?
As of the Oct 23, 2026 close, Quest Diagnostics Incorporated's market capitalization is $27.09B, classifying it as a large-cap company. Quest Diagnostics Incorporated operates in the Healthcare sector within the Diagnostics & Research industry.